brusatol / GSH Cancer Research Results

BRU, brusatol: Click to Expand ⟱
Features:
Brusatol is a quassinoid (highly oxygenated triterpenoid derivative) isolated from Brucea javanica. It is best known in oncology research as a potent functional inhibitor of the Nrf2 pathway, which places it at the center of redox regulation, chemoresistance, and mitochondrial stress in cancer cells.


Brusatol — brusatol is a naturally occurring quassinoid, a highly oxygenated degraded triterpenoid isolated mainly from Brucea javanica. It is best characterized as a preclinical small-molecule anticancer sensitizer that suppresses stress-response and survival signaling, with the strongest historical association being transient depletion of NRF2-dependent cytoprotective signaling. Its formal classification is a plant-derived natural product and experimental anticancer chemosensitizer. Standard abbreviations include BRU and BT. Mechanistically, current evidence no longer supports treating brusatol as a clean or selective NRF2 inhibitor; rather, NRF2 suppression appears to be one important downstream consequence of broader translational and short-lived protein depletion, with additional context-dependent effects on STAT3, AKT/mTOR, EGFR-linked signaling, EMT/metastasis programs, and ferroptosis susceptibility.

Primary mechanisms (ranked):

  1. Global translational suppression with preferential depletion of short-lived stress-survival proteins, including NRF2
  2. Functional suppression of the NRF2 antioxidant program with downregulation of HO-1, NQO1, GCLC and related redox-defense outputs
  3. ROS amplification and redox-vulnerability induction, especially in combination settings
  4. Inhibition of survival signaling pathways including STAT3 and, in some models, PI3K/AKT/mTOR
  5. Promotion of mitochondrial apoptosis with caspase activation and Bcl-2-family shift
  6. Anti-invasive and anti-metastatic activity via EMT suppression and reduced MMP/ROCK-associated migratory signaling
  7. Ferroptosis sensitization or induction in selected models through NRF2-system xCT-GSH axis disruption
  8. Chemosensitization and radiosensitization through collapse of adaptive cytoprotective resistance programs

Bioavailability / PK relevance: Native brusatol has meaningful delivery constraints and limited development maturity. Published PK work is mainly preclinical, including intravenous mouse and rat studies, tissue-distribution studies, metabolite identification, and formulation work designed to improve oral exposure. Nanoparticle and self-microemulsifying systems have been explored because practical systemic delivery and therapeutic index remain limiting issues.

In-vitro vs systemic exposure relevance: Many cell studies use submicromolar to low-micromolar concentrations, which may be pharmacologically active but are not yet anchored to a validated human exposure range because there is no established clinical dosing framework. Some mechanistic claims likely reflect concentration- and model-dependent pleiotropy. Combination efficacy appears more translationally relevant than assuming selective single-target inhibition at fixed in-vitro concentrations.

Clinical evidence status: Preclinical only. Evidence includes extensive in-vitro work and multiple animal studies showing tumor-growth inhibition and sensitization to chemotherapy or targeted therapy, but no established human oncology efficacy and no identified registered interventional cancer trial establishing clinical use of purified brusatol as an anticancer drug.

Mechanistic relevance of brusatol in cancer

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Protein translation suppression ↓ short-lived survival proteins ↓ protective proteins P-R Upstream cytotoxic driver Best current high-level interpretation. Explains why NRF2 falls rapidly but also why brusatol affects multiple unrelated pathways; reduces confidence in strict target selectivity.
2 NRF2 antioxidant program ↓ NRF2, ↓ HO-1, ↓ NQO1, ↓ GCLC ↓ NRF2 defense possible P-R Redox-defense collapse Historically central mechanism and still highly relevant functionally, especially for chemosensitization, but likely not exclusive or fully specific.
3 Oxidative stress increase ↑ ROS ↑ injury risk (context-dependent) R-G Redox crisis and death sensitization Often emerges after antioxidant-program suppression; especially important in combination with cisplatin, taxanes, trastuzumab, lapatinib, or ferroptosis-linked settings.
4 Mitochondrial apoptosis ↑ Bad or Bax signaling, ↓ Bcl-2, ↑ caspase-9, ↑ caspase-3 ↔ to ↑ toxicity risk R-G Execution of tumor cell death Common endpoint across models. Frequently linked to ROS accumulation and survival-pathway shutdown.
5 STAT3 and JAK kinase signaling ↓ JAK1/2, ↓ Src, ↓ STAT3, ↓ nuclear STAT3 ↔ R-G Reduced growth, survival, EMT, metastasis Supported strongly in HNSCC and HCC systems; likely important in subsets where STAT3 is dominant.
6 PI3K AKT mTOR axis ↓ PI3K, ↓ p-AKT, ↓ mTOR ↔ R-G Proliferation and survival suppression Observed in several tumor models; may be partly direct in some contexts and partly secondary to broader stress signaling collapse in others.
7 EGFR related signaling ↓ EGFR-TK activity, ↓ HER2-AKT-ERK signaling ↔ R-G Growth inhibition and targeted-therapy sensitization Evidence includes cell-free EGFR-TK inhibition and combination activity in HER2-positive models. Relevance is plausible but not yet as established as the redox-survival axes.
8 EMT and metastasis program ↓ EMT, ↓ migration, ↓ invasion, ↓ MMP2, ↓ MMP9, ↓ ROCK1 ↔ G Anti-metastatic effect Seen in colorectal, HCC, NSCLC, ESCC and other models. Often downstream of STAT3, AKT, or redox disruption.
9 Ferroptosis susceptibility ↑ ferroptosis sensitivity, ↓ GSH defense ↔ to ↑ oxidative vulnerability R-G Non-apoptotic death facilitation Growing 2025-2026 literature suggests this is mechanistically relevant in some cancers, but still appears context-dependent rather than universal.
10 Chemosensitization and radiosensitization ↑ chemo response, ↑ radio response ↔ to ↓ tissue tolerance G Resistance reversal One of the most reproducible translational themes. Benefit likely comes from disabling adaptive antioxidant and pro-survival buffering rather than from a single receptor-like target.
11 Clinical Translation Constraint Bioavailability limits, pleiotropy, toxicity interaction risk Potential collateral stress sensitization G Restrains development No established clinical oncology deployment. Preclinical PK is limited, formulation optimization is still active, and recent work suggests brusatol can worsen cisplatin nephrotoxicity by altering cisplatin pharmacokinetics.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.
Scientific Papers found: Click to Expand⟱
5695- BRU,    Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
- in-vitro, Lung, A549
NRF2↓, ChemoSen↑, Apoptosis↑, TumCP↓, TumCG↓, MRP1↓, GSH↓, cMyc↓,
5700- BRU,    Brusatol modulates the Nrf2/GCLC pathway to enhance ferroptosis in the treatment of oral squamous cell carcinoma
- in-vitro, Oral, CAL27
TumCG↓, Ferroptosis↑, TumCMig↓, NRF2↓, i-GSH↓, Iron↑, ROS↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GSH↓, 1,   i-GSH↓, 1,   Iron↑, 1,   NRF2↓, 2,   ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Ferroptosis↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 2,  

Migration ⓘ

TumCMig↓, 1,   TumCP↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   MRP1↓, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GSH, Glutathione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:385  Target#:137  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page